Sarath Kanekal

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes

Shannon M. Mumenthaler, Patricia Y.B. Ng, Amanda Hodge et al. · Molecular Cancer Therapeutics · 2009 · 152 citations · Full text

Medicine, Oncology, Pharmacology +16

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Hiroshi Yasui, Teru Hideshima, Makoto Hamasaki et al. · Blood · 2005 · 60 citations · Full text

Medicine, Oncology, Pharmacology +10

Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma

Tony Mok, Sarath Kanekal, Xiao Lin et al. · Cancer · 2001 · 30 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)

Donald Lavelle, Yogen Saunthararajah, Kestis Vaitkus et al. · Journal of Translational Medicine · 2010 · 30 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +12

<i>In vivo</i> and <i>in vitro</i> cytotoxicity of <i>R</i>‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells

Paola Neri, Hiroshi Yasui, Teru Hideshima et al. · British Journal of Haematology · 2006 · 18 citations

Medicine, Oncology, Pharmacology +13